Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 2 of 7, showing 10 Applications out of 68 total, starting on record 11, ending on 20

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

11.

ECCT/25/02/07   Clearance of High-Risk HPV
    A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts   
Principal Investigator(s)
1. Elizabeth Anne Bukusi
Site(s) in Kenya
1. KEMRI-RCTP (Kisumu county)
 
13-03-2025 View

12.

ECCT/25/02/05   Clearance of High-Risk HPV
    A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts   
Principal Investigator(s)
1. Irene Diana Odhiambo
Site(s) in Kenya
1. Victoria Biomedical Research Institute, Kisumu County Referral Hospital (Kisumu county)
 
07-03-2025 View

13.

ECCT/25/02/04   Clearance of High-Risk HPV
    A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts   
Principal Investigator(s)
1. Jacqueline Mirera
Site(s) in Kenya
1. CREA-N Machakos Level 5 Hospital Site (Machakos county)
 
06-03-2025 View

14.

ECCT/25/02/06   Clearance of High-Risk HPV
    A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts   
Principal Investigator(s)
1. Omu Anzala
Site(s) in Kenya
1. KAVI-Institute of Clinical Research (KAVI - ICR) (Nairobi City county)
 
06-03-2025 View

15.

ECCT/25/02/08   Clearance of High-Risk HPV
    A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts   
Principal Investigator(s)
1. Valentine Chepkorir Sing’oei
Site(s) in Kenya
1. KEMRI –USAMRD-A, Kombewa Clinical Research Centre (Kisumu county)
 
06-03-2025 View

16.

ECCT/24/06/04   ALNASA
    A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE       
Principal Investigator(s)
1. Jacqueline Mirera
Site(s) in Kenya
1. Clinical Research Health Network (CREA-N) (Machakos county)
 
23-10-2024 View

17.

ECCT/24/08/01   Evaluate clearance of HPV
    A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts   
Principal Investigator(s)
1. Fredrick Chite Asirwa
2. Kevin Makori Gesimba
Site(s) in Kenya
1. International Cancer Institute (ICI) (Uasin Gishu county)
2. Victoria Cancer Care and Research centre (Nyamira county)
 
16-10-2024 View

18.

ECCT/23/04/02   Shigella 53G study in Kenya
    Safety and feasibility of a Shigella sonnei 53G controlled human infection model in Kenyan adults: a dose finding and dose verification study   
Principal Investigator(s)
1. Melissa Kapulu
2. Fredrick Sawe
Site(s) in Kenya
KEMRI-Wellcome Trust Research Programme (KWTRP) Centre for Geographic Medical Research - Coast (CGMRC), Kilifi, Kenya.
 
21-08-2024 View

19.

ECCT/24/02/04   IGHID 12333
    IGHID 12333: Phase I study on the Pharmacokinetics of intravaginal, self-administered Artesunate vaginal pessaries among women in Kenya.IGHID 12333: Phase I study on the Pharmacokinetics of intravaginal, self-administered Artesunate vaginal pessaries among women in Kenya.   
Principal Investigator(s)
1. Chemtai Mungo
Site(s) in Kenya
Lumumba subcounty Hospital Kisumu
 
26-04-2024 View

20.

ECCT/23/11/04   AUB Study
    A phase 1, single-center, double-blind, randomized, placebo-controlled trial to assess the safety, tolerability and initial efficacy of AHC01 delivered via transcervical catheter in adult females (25-55 years), experiencing abnormal uterine bleeding and scheduled for a hysterectomy.   
Principal Investigator(s)
1. Dr Alice Kaaria
Site(s) in Kenya
Kenyatta National Hospital (KNH)
 
15-04-2024 View